Back to our regularly scheduled programA recent article on Cytosorbents stated:
"Following the heavy fall in price, Cytosorbents may be sending buy signals at present with its price-to-sales (or "P/S") ratio of 1.4x, considering almost half of all companies in the Medical Equipment industry in the United States have P/S ratios greater than 3.3x and even P/S higher than 8x aren't out of the ordinary"
Here's the math on what a Spectral SP would be using these quoted multiples and assuming just 40% penetration of their $2B USD target market ( low IMO)
Figures are in CAD $ at 1.35 FX and assume 350 M shares o/s
Multiple P/S. Projected SP (CAD)
1.4 X $4.32
3.3 X. $10.18
8 X $ 24.68
Hope this article is right about multiples - especially since this is an almost identical device - but only one that is on the verge of proving things out to the FDA
Jus sayin
MM